Research and Markets (http://www.researchandmarkets.com/research/828kfk/hairy_cell)
has announced the addition of the "Hairy
Cell Leukemia - Pipeline Review, H2 2014" report to their
offering.
This report provides comprehensive information on the therapeutic
development for Hairy Cell Leukemia, complete with comparative analysis
at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Hairy
Cell Leukemia and special features on late-stage and discontinued
projects.
This report features investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from this proprietary databases,
Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources, put together by this team.
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Hairy Cell Leukemia
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Amgen Inc.
-
AstraZeneca PLC
-
GlaxoSmithKline plc
-
MedImmune, LLC
-
Plexxikon Inc.
-
Astellas Pharma Inc.
-
Incyte Corporation
-
Stemline Therapeutics, Inc.
-
Onconova Therapeutics, Inc.
-
Inbiopro Solutions Pvt. Ltd.
-
Biogenomics Limited
For more information visit http://www.researchandmarkets.com/research/828kfk/hairy_cell
Copyright Business Wire 2014